<?xml version="1.0" encoding="UTF-8"?>
<p id="Par10">The preliminary studies indicate that chloroquine and hydroxychloroquine have the potential to improve disease outcomes and possibly slow COVID-19â€™s progression [
 <xref ref-type="bibr" rid="CR49">49</xref>]. Other in vitro and clinical studies demonstrated that the antiviral action of hydroxychloroquine might be effective in limiting SARS-CoV-2 infection [
 <xref ref-type="bibr" rid="CR49">49</xref>, 
 <xref ref-type="bibr" rid="CR50">50</xref>]. Further, a combination of hydroxychloroquine and azithromycin has also been used against the pathophysiology of COVID-19 [
 <xref ref-type="bibr" rid="CR51">51</xref>] and is under clinical trial against SARS-CoV-2.
</p>
